Oura launches US IPO with $40-$44 price range, 50M shares
- ŌURA launches IPO of 50M shares at $40-$44 price range
- Existing stockholders sell 36.5M shares; company sells 13.5M
- Expects 5.7M paid members by end of FY26, up 96% YoY
- Goldman Sachs, Morgan Stanley, J.P. Morgan lead the deal

*this image is generated using AI for illustrative purposes only.
Health intelligence platform ŌURA has launched its initial public offering of 50,000,000 shares of common stock on the Nasdaq Global Select Market under the ticker symbol "OURA." The offering price is expected to be between $40.00 and $44.00 per share.
The offering consists of 13,500,000 shares offered by ŌURA and 36,500,000 shares offered by certain existing stockholders. Underwriters have a 30-day option to purchase up to an additional 7,500,000 shares. ŌURA will not receive proceeds from the sale of shares by the selling stockholders.
Offering Structure
Goldman Sachs & Co. LLC, Morgan Stanley, J.P. Morgan, Allen & Company LLC, and Jefferies act as joint lead book-running managers. BofA Securities, Barclays, and Wells Fargo Securities are joint book-running managers. Citizens Capital Markets, KeyBanc Capital Markets, and Guggenheim Securities serve as book-running managers. Canaccord Genuity, Needham & Company, Raymond James, Rothschild & Co, Truist Securities, and William Blair are additional book-running managers. Robinhood acts as a co-manager.
Growth Metrics
ŌURA updated its S-1 filing on September 21, 2026, to reflect expectations of ending fiscal 2026 with approximately 5.7 million Paid Members. This represents 96 percent year-over-year growth. The company attributes this momentum primarily to strong sales of the Oura Ring 5.
| Metric | Value |
|---|---|
| Total Shares Offered | 50,000,000 |
| Price Range | $40.00 - $44.00 |
| Expected Paid Members (FY26) | 5.7 million |
| Member Growth (YoY) | 96% |
A registration statement on Form S-1 has been filed with the SEC but has not yet become effective. The securities may not be sold prior to effectiveness.
How might the significant portion of shares offered by existing stockholders impact early investor sentiment and potential selling pressure post-listing?
Will the 96% year-over-year member growth rate be sustainable as the wearable health market becomes increasingly saturated with competitors?
How will ŌURA allocate the proceeds from its portion of the IPO to drive future R&D or expansion into new product categories beyond the Oura Ring 5?

























